AKEBIA THERAPEUTICS INC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$82.0M
Doctors Paid
6,134
Transactions
91,466
2024 Total
$2.2M
Payment Breakdown by Category
Research$77.8M (94.8%)
Consulting$2.1M (2.6%)
Food & Beverage$628,007 (0.8%)
Travel$218,769 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $77.8M | 59,797 | 94.8% |
| Consulting Fee | $2.1M | 384 | 2.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 428 | 1.4% |
| Food and Beverage | $628,007 | 28,876 | 0.8% |
| Travel and Lodging | $218,769 | 663 | 0.3% |
| Education | $85,226 | 1,309 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $36,746 | 7 | 0.0% |
| Grant | $25,000 | 1 | 0.0% |
| Charitable Contribution | $17,210 | 1 | 0.0% |
Payments by Type
Research
$77.8M
59,797 transactions
General
$4.3M
31,669 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| AKB-6548-CI-0017 | $17.5M | 0 | 24,481 |
| AKB-6548-CI-0014 | $10.0M | 0 | 11,052 |
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) | $8.3M | 0 | 1,016 |
| A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | $7.7M | 6 | 5,355 |
| AKB-6548-CI-0015 | $7.5M | 0 | 7,375 |
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) | $6.0M | 0 | 1,394 |
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) | $3.6M | 0 | 1,197 |
| Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Effect of Ferric Citrate on Time to a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality vs Placebo in Adults With Advanced CKD | $3.0M | 0 | 36 |
| AKB-6548-CI-0016 | $2.2M | 0 | 2,038 |
| A Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Impact of Auryxia (Ferric Citrate) on Erythropoiesis-Stimulating Agent (ESA) Use, Intravenous (IV) Iron Use, Phosphate Control, and Anemia Control in Adult Participants on In-Center Hemodialysis or Home Dialysis | $1.8M | 0 | 35 |
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OR MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH INCIDENT DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE - CORRECTION/CONVERSION) | $1.5M | 0 | 301 |
| Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) | $1.3M | 0 | 19 |
| Safety of Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects: Vafseo Outcomes In-Center Experience | $1.2M | 0 | 1 |
| PHASE 2, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS STUDY OF ORAL VADADUSTAT FOR THE TREATMENT OF ANEMIA IN HEMODIALYSIS SUBJECTS CONVERTING FROM EPOETIN ALFA (FO2RWARD-2) | $645,053 | 0 | 96 |
| A PHASE 1B, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF VADADUSTAT IN HEMODIALYSIS SUBJECTS WITH ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE | $637,362 | 0 | 64 |
| A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease | $603,031 | 0 | 159 |
| AKB6548CI0017 | $572,828 | 0 | 769 |
| Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) | $543,458 | 0 | 2,344 |
| AKB6548CI0014 | $471,180 | 0 | 872 |
| AKB6548CI0016 | $427,508 | 0 | 495 |
| VADADUSTAT FOR THE PREVENTION AND TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN HOSPITLIZED PATIENTS WITH CORONAVIRUS DISEASE 2019 (COVID-19) | $352,670 | 0 | 3 |
| INVESTIGATOR STUDY | $280,507 | 0 | 4 |
| STUDY OF KRX-0502 (FERRIC CITRATE) DOSE REGIMENS IN SUBJECTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE AND IRON-DEFICIENCY ANEMIA | $265,276 | 0 | 60 |
| AKB6548CI0015 | $209,087 | 0 | 407 |
| Outcomes of iron deficiency anemia in non-dialysis dependent chronic kidney disease | $129,032 | 0 | 1 |
| 2018-FC-049 | $94,757 | 0 | 1 |
| Effect of Ferric Citrate on ESA utilization in ESRD patients with high Ferritin & low transferrin saturation: A Pilot project | $73,648 | 0 | 2 |
| TRANSITION TO FERRIC CITRATE AMONG HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS | $59,627 | 0 | 1 |
| A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function | $52,705 | 0 | 10 |
| Akebia AKI preclinical studies | $52,586 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Myles Wolf, Md, MD | Internal Medicine | Chicago, IL | $920,760 | $0 |
| Glenn Chertow, Md, MD | Internal Medicine | Stanford, CA | $221,935 | $0 |
| Dr. John Price, Md, MD | Internal Medicine | Glastonbury, CT | $186,500 | $0 |
| Dr. Ramon Mendez, M.d, M.D | Nephrology | Woodbridge, VA | $164,334 | $0 |
| Rebecca Hoffman, Md, MD | Allergy & Immunology | Wilmette, IL | $159,827 | $0 |
| Dr. Robert Mensah, Dds, DDS | Orthodontics and Dentofacial Orthopedics | Largo, MD | $131,575 | $0 |
| Jay Wish, Md, MD | Nephrology | Indianapolis, IN | $95,042 | $0 |
| Rajiv Agarwal, M.d, M.D | Nephrology | Indianapolis, IN | $78,564 | $0 |
| German Hernandez, M.d, M.D | Internal Medicine | El Paso, TX | $76,093 | $0 |
| Ashte Collins, M.d, M.D | Internal Medicine | Washington, DC | $70,313 | $0 |
| Christopher Gisler, Md, MD | Internal Medicine | Pittsburgh, PA | $60,209 | $0 |
| Nimish Naik, M.d, M.D | Nephrology | Wexford, PA | $55,252 | $0 |
| Dr. Ajit Sawhney, M.d, M.D | Nephrology | Fountain Valley, CA | $48,946 | $0 |
| Dr. Sunil Patel, D.o, D.O | Nephrology | Apple Valley, CA | $45,344 | $0 |
| Joel Neugarten, Md, MD | Nephrology | Bronx, NY | $43,162 | $0 |
| Richard Cottiero, Md, MD | Internal Medicine | Las Vegas, NV | $34,933 | $0 |
| Dr. Wolfgang Winkelmayer, M.d., Sc.d, M.D., SC.D | Internal Medicine | Houston, TX | $32,430 | $0 |
| Unknown Provider | — | — | $30,684 | $0 |
| Dr. Rohit Pankhaniya, Md, MD | Nephrology | Port Charlotte, FL | $29,865 | $0 |
| Carl Dukes, Md, MD | Specialist | San Antonio, TX | $27,759 | $0 |
| Dr. Mark Koury, Md, MD | Internal Medicine | Nashville, TN | $26,206 | $0 |
| Richard Lund, M.d, M.D | Nephrology | Omaha, NE | $19,992 | $0 |
| Anjay Rastogi, Md, MD | Nephrology | Los Angeles, CA | $19,577 | $0 |
| Luis Alvarez, Md, MD | Nephrology | Palo Alto, CA | $18,720 | $0 |
| Dr. Kamyar Kalantar-Zadeh, M.d, M.D | Nephrology | Orange, CA | $18,091 | $0 |
About AKEBIA THERAPEUTICS INC
AKEBIA THERAPEUTICS INC has made $82.0M in payments to 6,134 healthcare providers, recorded across 91,466 transactions in the CMS Open Payments database. In 2024, the company paid $2.2M. The top product by payment volume is Auryxia ($6.9M).
Payments were distributed across 92 medical specialties. The top specialty by payment amount is Internal Medicine ($1.8M to 893 doctors).
Payment categories include: Food & Beverage ($628,007), Consulting ($2.1M), Research ($77.8M), Travel & Lodging ($218,769).
AKEBIA THERAPEUTICS INC is associated with 3 products in the CMS Open Payments database.